Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Likes Concept Of Low-Cost Brand Alternatives As ‘Glide Path’ To No Rebates

Executive Summary

Approach could be useful for quickly lowering the cost of insulins, Express Scripts’ Miller points out.

You may also be interested in...



Gilead Lowering HCV Drug List Prices With Authorized Generics

Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.

Express Scripts Pushing Manufacturers To Lower List Prices By Offering Cheaper Brand Alternatives

Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.

Lowering Insulin Costs: Sanofi Seeks HHS Support For Expanding Assistance To Medicare Patients

HHS endorsement of company-sponsored discount programs for cash-paying customers with Medicare would be preferable to lowering list pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel